Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / CCND1

CCND1

Basics

Aliases:
This biomarker is also known as:
  • PRAD1,
  • B-cell lymphoma 1 protein,
  • BCL-1,
  • B-cell CLL/lymphoma 1,
  • BCL-1 oncogene,
  • D11S287E,
  • BCL1,
  • U21B31,
  • PRAD1 oncogene,
  • cyclin D1,
  • G1/S-specific cyclin-D1,
  • cyclin D1 (PRAD1: parathyroid adenomatosis 1),

View in BioMuta

Description…

CCND1 is a member of the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. CCND1 forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: CCND1

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

No additional breast data available.

Performance Comment

CCND1 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place October 15–16, 2015 in Bethesda, Maryland.

Announcement 04/08/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held October 15-16, 2015 on the NCI campus. More information will be available later this summer.

Announcement